Physician profile
Mark Brescia
NPI 1154537017
$2,787.94
in general payments reported to CMS, 2019-2025
29 companies · $237 in 2025
The $237 reported for 2025 was more than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $588 · 2020: $532 · 2021: $733 · 2022: $467 · 2023: $110 · 2024: $120 · 2025: $237.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $468.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $467.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celularity INC. | $1,012.00 | 2019-2021 | |
| Abbvie INC. | $300.73 | 2019-2023 | Liletta, Lo Loestrin Fe, Orilissa |
| Organon LLC | $288.85 | 2021-2024 | |
| Mayne Pharma Commercial LLC | $205.18 | 2021-2025 | |
| Astellas Pharma US INC | $177.16 | 2024-2025 | Veozah |
| Gynesonics, INC. | $111.63 | 2021 | |
| Hologic Sales and Service, LLC | $78.13 | 2020-2023 | Coolseal Generator |
| Bayer Healthcare Pharmaceuticals INC. | $75.92 | 2019-2025 | |
| Therapeuticsmd, INC. | $59.49 | 2019-2021 | |
| Allergan, INC. | $57.27 | 2019 | |
| Lupin INC. | $50.87 | 2019-2020 | |
| Avion Pharmaceuticals | $38.90 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $36.25 | 2019-2020 | |
| Exeltis, USA INC. | $30.73 | 2024-2025 | Slynd |
| Scynexis, INC. | $29.39 | 2021-2022 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Minerva Surgical, INC | $28.18 | 2019-2021 | |
| Avanos Medical | $27.13 | 2019 | |
| Coopersurgical, INC. | $26.42 | 2020 | |
| Sage Therapeutics, LLC | $15.00 | 2019 | |
| Pfizer INC. | $14.99 | 2021 | |
| Bausch Health US, LLC | $14.91 | 2023 | Aplenzin, Wellbutrin |
| Shire North American Group INC | $14.21 | 2019 | |
| Duchesnay USA Incorporated | $14.20 | 2019 | |
| Dysis Medical, INC. | $14.11 | 2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $13.81 | 2024 | Trintellix |
| Evofem Biosciences, INC. | $13.77 | 2022 | |
| Exact Sciences Corporation | $13.66 | 2023 | Cologuard Collection Kit |
| Medicem INC. | $12.55 | 2021 | |
| Myovant Sciences INC. | $12.50 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Brescia listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.